Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification
- 24 May 2021
- journal article
- editorial
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), 350-353
- https://doi.org/10.1016/j.clcc.2021.05.008
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAActJournal of Clinical Oncology, 2020
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.Journal of Clinical Oncology, 2020
- Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158Annals of Oncology, 2019
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid TumorsJAMA Oncology, 2018
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2017
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canalAnnals of Oncology, 2017
- Molecular characterization of squamous cell carcinoma of the anal canal (SCCA).Journal of Clinical Oncology, 2017
- Epidemiology of Anal Canal CancerSurgical Oncology Clinics of North America, 2017
- Anal Cancer: Current and Future MethodologyCancer Investigation, 2006
- Combined therapy for cancer of the anal canalDiseases of the Colon & Rectum, 1993